Progenics Pharmaceuticals (PGNX) 10-Q 2015 Q2 Quarterly report

Exhibit 12.1

Progenics Pharmaceuticals, Inc.

Ratio of Earnings (Loss) to Combined Fixed Charges and Preferred Stock Dividends

(in thousands)

	Six MonthsEndedJune 30,			Years Ended December 31,
	2015			2014		2013			2012			2011		2010
Determination of earnings (loss):
Income (loss) from operations	$	(21,951	)	$	4,410	$	(42,934	)	$	(35,431	)	$	10,381	$	(69,820	)
Add:
Fixed charges		181			373		710			410			695		709
Earnings (loss), as adjusted	$	(21,770	)	$	4,783	$	(42,224	)	$	(35,021	)	$	11,076	$	(69,111	)
Fixed charges:
Estimate of interest within rental expense		181			373		710			410			695		709
Fixed charges	$	181		$	373	$	710		$	410		$	695	$	709
Preferred stock dividends	$	-		$	-	$	-		$	-		$	-	$	-
Ratio of earnings (loss) to fixed charges and preferred stock dividends		*			13		*			*			16		*
Coverage deficiency amount for total fixed charges and preferred stock dividends (1)	$	21,951		$	-	$	42,934		$	35,431		$	-	$	69,820

⁽¹⁾ For the years ended 2010, 2012, 2013 and for the six months ended June 30, 2015, the Company's coverage ratio is less than one-to-one and it must generate additional earnings of these specified amounts to achieve a coverage ratio of 1:1.